Compare Summit Therapeutics Inc (SMMT) vs Truist Financial Corporation Common Stock (TFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Truist Financial Corporation Common Stock — how do they compare? Summit Therapeutics Inc trades at $17.33 (market cap $14.33B), while Truist Financial Corporation Common Stock trades at $46.2 (market cap $55.68B). The key difference: Truist Financial Corporation Common Stock is far larger — about 3.9× Summit Therapeutics Inc's market cap, and Truist Financial Corporation Common Stock pays a 4.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Truist Financial Corporation Common Stock for 0 Days on average.
| SMMT | TFC | |
|---|---|---|
Market Cap | $14.33B | $55.68B |
Volume | 8,167,213 | 7,292,374 |
Sector | Health | Financials |
52-Week High | $26.38 | $55.81 |
52-Week Low | $12.43 | $41.09 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $13.66B | $121.94B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Truist Financial Corporation Common Stock
Truist Financial provides consumer and commercial banking, wealth management, insurance, and investment services in the United States.
Read more on TFC →
